Business
Investors in drugmaker Mesoblast sweat on crucial capital raising – Sydney Morning Herald
The stem cell giant says it needs cash from its existing partnerships to ‘continue as a going concern’.
The ability of the group to continue as a going concern and realise its assets and discharge its liabilities in the normal course of business are dependent on cash inflows from successfully completing the private placement, as well as from existing strategic and financing partnerships, the auditors report said.
Analysts at Bell Potter noted last month that Mesoblasts balance sheet could come under pressure in the 2022 financial year if there were any hiccups with agreements and payments from partners…
-
General20 hours agoChinese Communist Party body replaces 11 members amid corruption purge
-
General23 hours agoACT government considers making public transport free for more Canberrans
-
Noosa News6 hours agoWoman charged with murder over fire that killed mother, boys
-
Noosa News24 hours agoMan in custody after fatal stabbing near state border